CN103124727B - 取代的3-苯基-1,2,4-噁二唑化合物 - Google Patents
取代的3-苯基-1,2,4-噁二唑化合物 Download PDFInfo
- Publication number
- CN103124727B CN103124727B CN201180045224.9A CN201180045224A CN103124727B CN 103124727 B CN103124727 B CN 103124727B CN 201180045224 A CN201180045224 A CN 201180045224A CN 103124727 B CN103124727 B CN 103124727B
- Authority
- CN
- China
- Prior art keywords
- oxadiazol
- benzyl
- carboxylic acid
- azetidine
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC1(CN(CCC(*)=O)C1)O Chemical compound CC1(CN(CCC(*)=O)C1)O 0.000 description 5
- JGBCNINJBWKTEA-UHFFFAOYSA-N CC(C1(CCCC(O)=O)CCCC2)=CC=CC=[O]3C12OCC3 Chemical compound CC(C1(CCCC(O)=O)CCCC2)=CC=CC=[O]3C12OCC3 JGBCNINJBWKTEA-UHFFFAOYSA-N 0.000 description 1
- LNXJYRJPEFXNCK-UHFFFAOYSA-N CC(CCNCC(c(cc1)ccc1-c1n[o]c(CCCCCCc(cc2)ccc2Cl)n1)O)=O Chemical compound CC(CCNCC(c(cc1)ccc1-c1n[o]c(CCCCCCc(cc2)ccc2Cl)n1)O)=O LNXJYRJPEFXNCK-UHFFFAOYSA-N 0.000 description 1
- NNYOABTZLCYYDN-UHFFFAOYSA-N CC(CN(CCC1)CC1C(O)=O)O Chemical compound CC(CN(CCC1)CC1C(O)=O)O NNYOABTZLCYYDN-UHFFFAOYSA-N 0.000 description 1
- BEAZDEAQCGOQMR-UHFFFAOYSA-N CCN(C1)CC1(C(N1)=O)NC1=O Chemical compound CCN(C1)CC1(C(N1)=O)NC1=O BEAZDEAQCGOQMR-UHFFFAOYSA-N 0.000 description 1
- IQSLFTXFNOGVKK-UHFFFAOYSA-N CCN(C1)CC1C(O)=O Chemical compound CCN(C1)CC1C(O)=O IQSLFTXFNOGVKK-UHFFFAOYSA-N 0.000 description 1
- AORFJQJCXUUQJW-VOTSOKGWSA-N CCOC(/C=C/C1(CCOCC1)c1cccc(C(F)(F)F)c1)=O Chemical compound CCOC(/C=C/C1(CCOCC1)c1cccc(C(F)(F)F)c1)=O AORFJQJCXUUQJW-VOTSOKGWSA-N 0.000 description 1
- XPEFLWZUCWGSID-MDYZWHIJSA-N C[C@@H](CO)COc(c(C)c1)c(C)cc1-c1n[o]c(CC2(c3ccccc3)OCCCC2)n1 Chemical compound C[C@@H](CO)COc(c(C)c1)c(C)cc1-c1n[o]c(CC2(c3ccccc3)OCCCC2)n1 XPEFLWZUCWGSID-MDYZWHIJSA-N 0.000 description 1
- RXIYIVCVCKGWPU-UHFFFAOYSA-N Clc1ccc(C2(COCc3nc(-c4ccc(CBr)cc4)n[o]3)CCC2)cc1 Chemical compound Clc1ccc(C2(COCc3nc(-c4ccc(CBr)cc4)n[o]3)CCC2)cc1 RXIYIVCVCKGWPU-UHFFFAOYSA-N 0.000 description 1
- ANRTVWAZQXYUEP-UHFFFAOYSA-N N#Cc1ccc(CN(C2)CC2C(O)=O)cc1 Chemical compound N#Cc1ccc(CN(C2)CC2C(O)=O)cc1 ANRTVWAZQXYUEP-UHFFFAOYSA-N 0.000 description 1
- CTSVGDANGUFMHS-UHFFFAOYSA-N OC(C1CN(Cc(cc2)ccc2-c2n[o]c(CCC(CCCC3)(C3=O)c3ccccc3)n2)C1)=O Chemical compound OC(C1CN(Cc(cc2)ccc2-c2n[o]c(CCC(CCCC3)(C3=O)c3ccccc3)n2)C1)=O CTSVGDANGUFMHS-UHFFFAOYSA-N 0.000 description 1
- XOCZVRFYLKLZAH-UHFFFAOYSA-N OC(C1CN(Cc(cc2)ccc2-c2n[o]c(CCC3(CCCCC3)c3ccccc3)n2)C1)=O Chemical compound OC(C1CN(Cc(cc2)ccc2-c2n[o]c(CCC3(CCCCC3)c3ccccc3)n2)C1)=O XOCZVRFYLKLZAH-UHFFFAOYSA-N 0.000 description 1
- QOLLNTJRFQGJNS-UHFFFAOYSA-N OC(C1CN(Cc(cc2)ccc2-c2n[o]c(CCC3(CCOCC3)c3cccc(C(F)(F)F)c3)n2)C1)=O Chemical compound OC(C1CN(Cc(cc2)ccc2-c2n[o]c(CCC3(CCOCC3)c3cccc(C(F)(F)F)c3)n2)C1)=O QOLLNTJRFQGJNS-UHFFFAOYSA-N 0.000 description 1
- GBRMBQHBAUHGPO-UHFFFAOYSA-N OC(C1CN(Cc(cc2)ccc2-c2n[o]c(CCCC3(CCCCC3)c(cc3)ccc3F)n2)C1)=O Chemical compound OC(C1CN(Cc(cc2)ccc2-c2n[o]c(CCCC3(CCCCC3)c(cc3)ccc3F)n2)C1)=O GBRMBQHBAUHGPO-UHFFFAOYSA-N 0.000 description 1
- SZWQNSCFKXIOBS-UHFFFAOYSA-N OC(CC(CCC1)CC1C(O)=O)S Chemical compound OC(CC(CCC1)CC1C(O)=O)S SZWQNSCFKXIOBS-UHFFFAOYSA-N 0.000 description 1
- RIPPHMJFMQFARD-UHFFFAOYSA-N OC(CCC1(c2ccccc2)OCCCC1)=O Chemical compound OC(CCC1(c2ccccc2)OCCCC1)=O RIPPHMJFMQFARD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36592310P | 2010-07-20 | 2010-07-20 | |
| US61/365,923 | 2010-07-20 | ||
| PCT/US2011/044597 WO2012012477A1 (en) | 2010-07-20 | 2011-07-20 | Substituted 3-phenyl-1,2,4-oxadiazole compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103124727A CN103124727A (zh) | 2013-05-29 |
| CN103124727B true CN103124727B (zh) | 2015-03-25 |
Family
ID=44628993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180045224.9A Expired - Fee Related CN103124727B (zh) | 2010-07-20 | 2011-07-20 | 取代的3-苯基-1,2,4-噁二唑化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8822510B2 (enExample) |
| EP (1) | EP2595969B1 (enExample) |
| JP (1) | JP5788507B2 (enExample) |
| CN (1) | CN103124727B (enExample) |
| ES (1) | ES2539256T3 (enExample) |
| WO (1) | WO2012012477A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5869579B2 (ja) * | 2010-09-24 | 2016-02-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用 |
| US8629282B2 (en) | 2010-11-03 | 2014-01-14 | Bristol-Myers Squibb Company | Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseases |
| ES2782509T3 (es) | 2012-07-02 | 2020-09-15 | Monsanto Technology Llc | Procedimiento para la preparación de 1,2,4-oxadiazoles 3,5-disustituidos |
| US8957051B2 (en) * | 2012-10-04 | 2015-02-17 | Allergan, Inc. | Bicyclic 1, 2, 4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators |
| US8859598B2 (en) | 2012-10-04 | 2014-10-14 | Allergan, Inc. | 1, 2, 4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators |
| TWI613182B (zh) | 2013-02-21 | 2018-02-01 | 必治妥美雅史谷比公司 | 雙環化合物 |
| WO2015073140A1 (en) * | 2013-11-14 | 2015-05-21 | Allergan, Inc. | 1,3,4-alkenyl oxadiazole amino acid derivatives as sphingosine-1-phosphate receptors' modulators |
| WO2015108577A1 (en) * | 2014-01-15 | 2015-07-23 | Allergan, Inc. | Diphenyl urea derivatives as formyl peptide receptor modulators |
| TWI689487B (zh) | 2014-08-20 | 2020-04-01 | 美商必治妥美雅史谷比公司 | 經取代雙環化合物 |
| HRP20221417T1 (hr) * | 2015-11-13 | 2023-02-03 | Oppilan Pharma Ltd. | Heterociklički spojevi za liječenje bolesti |
| US11147275B2 (en) * | 2017-11-23 | 2021-10-19 | Basf Se | Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi |
| CN115197282B (zh) * | 2021-04-12 | 2024-10-11 | 中科催化新技术(大连)股份有限公司 | 一种吡喃糖苷衍生物的制备方法 |
| CN115197186B (zh) * | 2021-04-12 | 2024-04-16 | 中科催化新技术(大连)股份有限公司 | 一种生物质基吡喃糖苷衍生物的制备方法 |
| CN116375671A (zh) * | 2021-12-24 | 2023-07-04 | 晶美晟光电材料（南京）有限公司 | 一种包含四氢吡喃结构的液晶化合物的制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003105771A2 (en) * | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
| CN1894225A (zh) * | 2003-12-17 | 2007-01-10 | 默克公司 | 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯 |
| CN101203512A (zh) * | 2005-04-22 | 2008-06-18 | 第一三共株式会社 | 杂环化合物 |
| WO2010033701A2 (en) * | 2008-09-19 | 2010-03-25 | Genzyme Corporation | Inhibitors of sphingosine kinase 1 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| JPS6480026A (en) | 1987-09-21 | 1989-03-24 | Mitsubishi Electric Corp | Resist coater |
| US6069143A (en) | 1994-12-20 | 2000-05-30 | Smithkline Beecham Corporation | Fibrinogen receptor antagonists |
| WO2003062252A1 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Edg receptor agonists |
| WO2003062248A2 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
| CA2472680A1 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
| AU2003217764A1 (en) | 2002-03-01 | 2003-09-16 | Merck & Co., Inc. | Aminoalkylphosphonates and related compounds as edg receptor agonists |
| TW200505442A (en) | 2003-05-19 | 2005-02-16 | Genomics Inst Of The Novartis Res Foundation | Immunosuppressant compounds and compositions |
| TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| AU2005241056A1 (en) | 2004-05-04 | 2005-11-17 | Merck & Co., Inc. | 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| AU2005299851B2 (en) | 2004-10-22 | 2011-03-17 | Merck Sharp & Dohme Corp. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists |
| CA2596990A1 (en) | 2005-02-14 | 2006-08-24 | University Of Virginia Patent Foundation | Sphingosine 1-phosphate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups |
| RU2404178C2 (ru) | 2005-03-23 | 2010-11-20 | Актелион Фармасьютиклз Лтд | Новые производные тиофена в качестве агонистов рецептора сфингозин-1-фосфата-1 |
| WO2006131336A1 (en) | 2005-06-08 | 2006-12-14 | Novartis Ag | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS |
| CA2619101A1 (en) | 2005-08-23 | 2007-03-01 | Irm Llc | Immunosuppressant compounds and compositions |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| EP2010524A2 (en) | 2006-03-21 | 2009-01-07 | Epix Delaware, Inc. | S1p receptor modulating compounds |
| MX2008012738A (es) | 2006-04-03 | 2009-02-06 | Astellas Pharma Inc | Heterocompuesto. |
| JP2009269819A (ja) | 2006-08-25 | 2009-11-19 | Asahi Kasei Pharma Kk | アミン化合物 |
| KR101470659B1 (ko) | 2006-09-07 | 2014-12-08 | 액테리온 파마슈티칼 리미티드 | 면역조절제로서 피리딘-4-일 유도체 |
| TWI408139B (zh) | 2006-09-07 | 2013-09-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| MX2009002234A (es) | 2006-09-08 | 2009-03-16 | Actelion Pharmaceuticals Ltd | Derivados de piridin-3-il como agentes inmunomoduladores. |
| RU2442780C2 (ru) | 2006-09-21 | 2012-02-20 | Актелион Фармасьютиклз Лтд | Фенильные производные и их применение в качестве иммуномодуляторов |
| JP2010513283A (ja) * | 2006-12-15 | 2010-04-30 | アボット・ラボラトリーズ | 新規なオキサジアゾール化合物 |
| US8217027B2 (en) | 2006-12-21 | 2012-07-10 | Abbott Laboratories | Sphingosine-1-phosphate receptor agonist and antagonist compounds |
| GB0625648D0 (en) | 2006-12-21 | 2007-01-31 | Glaxo Group Ltd | Compounds |
| DK2125797T3 (da) | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
| EP2014653A1 (en) | 2007-06-15 | 2009-01-14 | Bioprojet | Novel dicarboxylic acid derivatives as S1P1 receptor agonists |
| US8202865B2 (en) | 2007-10-04 | 2012-06-19 | Merck Serono Sa | Oxadiazole derivatives |
| KR20100092473A (ko) | 2007-11-01 | 2010-08-20 | 액테리온 파마슈티칼 리미티드 | 신규한 피리미딘 유도체 |
| WO2010065760A1 (en) * | 2008-12-04 | 2010-06-10 | Exelixis, Inc. | Imidazo [1,2a] pyridine derivatives, their use as s1p1 agonists and methods for their production |
| EP2202232A1 (en) * | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| US8404672B2 (en) | 2009-01-23 | 2013-03-26 | Bristol-Meyers Squibb Company | Substituted heterocyclic compounds |
| JP2012515787A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体 |
| ES2405054T3 (es) | 2009-01-23 | 2013-05-30 | Bristol-Myers Squibb Company | Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| EP2592071B1 (en) | 2009-10-29 | 2019-09-18 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
| JP5735634B2 (ja) | 2010-04-23 | 2015-06-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | スフィンゴシン−１−リン酸受容体１アゴニストとしての４−（５−イソオキサゾリルまたは５−ピラゾリル−１，２，４−オキサジアゾール−３−イル）−マンデル酸アミド化合物 |
| JP5869579B2 (ja) | 2010-09-24 | 2016-02-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用 |
| US8629282B2 (en) | 2010-11-03 | 2014-01-14 | Bristol-Myers Squibb Company | Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseases |
-
2011
- 2011-07-20 CN CN201180045224.9A patent/CN103124727B/zh not_active Expired - Fee Related
- 2011-07-20 JP JP2013520827A patent/JP5788507B2/ja not_active Expired - Fee Related
- 2011-07-20 US US13/811,032 patent/US8822510B2/en active Active
- 2011-07-20 ES ES11736263.2T patent/ES2539256T3/es active Active
- 2011-07-20 EP EP20110736263 patent/EP2595969B1/en not_active Not-in-force
- 2011-07-20 WO PCT/US2011/044597 patent/WO2012012477A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003105771A2 (en) * | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
| CN1894225A (zh) * | 2003-12-17 | 2007-01-10 | 默克公司 | 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯 |
| CN101203512A (zh) * | 2005-04-22 | 2008-06-18 | 第一三共株式会社 | 杂环化合物 |
| WO2010033701A2 (en) * | 2008-09-19 | 2010-03-25 | Genzyme Corporation | Inhibitors of sphingosine kinase 1 |
Non-Patent Citations (1)
| Title |
|---|
| Discovery of novel sphingosine kinase-1 inhibitors.Part 2;Yibin Xiang et al.;《Bioorganic & Medicinal Chemistry Letters》;20100617;第20卷(第15期);4550-4554 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103124727A (zh) | 2013-05-29 |
| JP5788507B2 (ja) | 2015-09-30 |
| ES2539256T3 (es) | 2015-06-29 |
| US20130158001A1 (en) | 2013-06-20 |
| WO2012012477A1 (en) | 2012-01-26 |
| EP2595969A1 (en) | 2013-05-29 |
| EP2595969B1 (en) | 2015-04-22 |
| US8822510B2 (en) | 2014-09-02 |
| JP2013531070A (ja) | 2013-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103124727B (zh) | 取代的3-苯基-1,2,4-噁二唑化合物 | |
| EP2592071B1 (en) | Tricyclic heterocyclic compounds | |
| EP2382212B1 (en) | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases | |
| US11040035B2 (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
| EP3164395B1 (en) | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | |
| CN103237795B (zh) | 经取代的噁二唑化合物及其作为s1p1激动剂的用途 | |
| CN102361868A (zh) | 作为1-磷酸-鞘氨醇激动剂的吡唑-1，2，4-噁二唑衍生物 | |
| US8629282B2 (en) | Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseases | |
| ES2533095T3 (es) | Agonistas de receptores de esfingosina-1-fosfato | |
| JP2012515788A (ja) | 自己免疫疾患および炎症性疾患の処置における、ｓ１ｐアゴニストとしての置換オキサジアゾール誘導体 | |
| JP2025510512A (ja) | Ｌｐａ受容体活性と関連する状態の処置のための化合物および組成物 | |
| AU2021249530A1 (en) | Compounds active towards nuclear receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150325 Termination date: 20170720 |